CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for T Man Pharmaceutical PCL is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

T Man Pharmaceutical PCL
69/1 Soi Bangkhunthian 14
Samaedum, Bangkhunthian
Phone: +66 24151007p:+66 24151007 BANGKOK, 10150  Thailand Ticker: TMANTMAN
Business Summary
T.Man Pharmaceutical Public Company Limited is engaged in purchasing, importing, manufacturing, original equipment manufacturing, distributing and exporting of modern medicines, traditional medicine, dietary supplements, and health care products for the healthcare industry with subsidiaries as manufacturers. Its segments include manufactured products under own brand, manufactured products under third parties’ brand and trading products. With a diverse range of manufacturing machinery, it can produce various types of pharmaceutical products, meeting the needs of every consumer. Its production capabilities include tablets, capsules, powders, liquids, and semisolids. It offers capsule products, including both hard and soft capsules in various sizes, all made with imported, high-quality raw materials. Its product range covers a wide range of diseases and comes in various forms, including uncoated tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, and suppositories.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board SunisaSorchaithanasuk 12/23/2022 12/23/2022
Chief Executive Officer, Executive Director PraponThanachotphan
Chief Financial Officer, Company Secretary DarikaTaengtrong 9/13/2023 9/13/2023
10 additional Officers and Directors records available in full report.

General Information
Stock Exchange: BAK
Fax Number: +66 24161241


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024